Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 100 | 3.86 |
09:34 ET | 1200 | 4.15 |
09:36 ET | 1600 | 4.15 |
09:38 ET | 1573 | 4.17 |
09:39 ET | 100 | 4.42 |
09:41 ET | 801 | 4 |
10:39 ET | 100 | 4.21 |
11:00 ET | 100 | 4.02 |
11:06 ET | 300 | 4.01 |
11:09 ET | 250 | 4.0869 |
11:56 ET | 327 | 4.02 |
12:23 ET | 100 | 4.15 |
12:48 ET | 100 | 4.105 |
01:57 ET | 200 | 4.11 |
02:47 ET | 100 | 4.1056 |
02:58 ET | 100 | 4.115 |
03:16 ET | 100 | 4.13 |
03:52 ET | 100 | 4.09 |
03:59 ET | 6103 | 4.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 226.3M | -2.2x | --- |
Merrimack Pharmaceuticals Inc | 223.7M | -0.3x | --- |
Eliem Therapeutics Inc | 228.9M | -14.7x | --- |
Pyxis Oncology Inc | 229.7M | -2.8x | --- |
Aldeyra Therapeutics Inc | 229.9M | -7.6x | --- |
Ovid Therapeutics Inc | 229.2M | -4.5x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $226.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.